Latest & greatest articles for azithromycin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on azithromycin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on azithromycin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for azithromycin

41. WITHDRAWN: Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever). (Full text)

WITHDRAWN: Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever). Review status: Current question - no update intended. Azithromycin treatments are included in the review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). (Thaver D, Zaidi AKM, Critchley JA, Azmatullah A, Madni SA, Bhutta ZA. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). Cochrane Database of Systematic Reviews 2008, Issue 4. Art (...) . No.: CD004530. DOI: 10.1002/14651858.CD004530.pub3.)   This latter review is being updated, and will be published in late 2011.Enteric fever (typhoid and paratyphoid fever) is potentially fatal. Infection with drug-resistant strains of the causative organism Salmonella enterica serovar Typhi or Paratyphi increases morbidity and mortality. Azithromycin may have better outcomes in people with uncomplicated forms of the disease.To compare azithromycin with other antibiotics for treating uncomplicated enteric

2011 Cochrane PubMed

42. Azithromycin ophthalmic solution (Azidrop®) for purulent bacterial or trachomal conjunctivitis

Azithromycin ophthalmic solution (Azidrop®) for purulent bacterial or trachomal conjunctivitis 2010. DAR No 7. Azithromycin ophthalmic solution (Azidrop®) for purulent bacterial or trachomal conjunctivitis - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 7. Azithromycin ophthalmic solution (Azidrop®) for purulent bacterial or trachomal conjunctivitis DAR No 7. Azithromycin ophthalmic solution (Azidrop®) for purulent bacterial (...) or trachomal conjunctivitis Content tools Share it Similar efficacy at a higher cost Azithromycin in topical ophthalmic form is indicated in the treatment of susceptible strains of bacterial conjunctivitis and trachoma related conjunctivitis caused by Chlamydia trachomatis. The majority of purulent bacterial conjunctivitis cure spontaneously, and azithromycin has shown a similar efficacy and safety profile to tobramycin. There are no trials comparing other antibiotics. Although its posology is much more

2011 Drug and Therapeutics Bulletin of Navarre (Spain)

43. Azithromycin for treating uncomplicated malaria. (Full text)

Azithromycin for treating uncomplicated malaria. To prevent the development of drug resistance, the World Health Organization (WHO) recommends treating malaria with combination therapy. Azithromycin, an antibiotic with antimalarial properties, may be a useful additional option for antimalarial therapy.To compare the use of azithromycin alone or in combination with other antimalarial drugs with the use of alternative antimalarial drugs for treating uncomplicated malaria caused by Plasmodium (...) falciparum or Plasmodium vivax.We searched the Cochrane Infectious Diseases Group Specialized Register (August 2010); CENTRAL (The Cochrane Library Issue 3, 2010); MEDLINE (1966 to August 2010); EMBASE (1974 to August 2010); LILACS (August 2010); the metaRegister of Controlled Trials (mRCT, August 2010); conference proceedings; and reference lists. We also contacted researchers and a pharmaceutical company.Randomized controlled trials comparing azithromycin, either alone or combined with another

2011 Cochrane PubMed

44. Azithromycin for prevention of exacerbations of COPD. (Full text)

Azithromycin for prevention of exacerbations of COPD. Acute exacerbations adversely affect patients with chronic obstructive pulmonary disease (COPD). Macrolide antibiotics benefit patients with a variety of inflammatory airway diseases.We performed a randomized trial to determine whether azithromycin decreased the frequency of exacerbations in participants with COPD who had an increased risk of exacerbations but no hearing impairment, resting tachycardia, or apparent risk of prolongation (...) of the corrected QT interval.A total of 1577 subjects were screened; 1142 (72%) were randomly assigned to receive azithromycin, at a dose of 250 mg daily (570 participants), or placebo (572 participants) for 1 year in addition to their usual care. The rate of 1-year follow-up was 89% in the azithromycin group and 90% in the placebo group. The median time to the first exacerbation was 266 days (95% confidence interval [CI], 227 to 313) among participants receiving azithromycin, as compared with 174 days (95% CI

2011 NEJM PubMed

45. Azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in Bangladesh: an open-label randomized, controlled clinical trial (Full text)

Azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in Bangladesh: an open-label randomized, controlled clinical trial In recent studies, the combination of azithromycin and artesunate has proven to be a promising alternative for the treatment of uncomplicated falciparum malaria.We conducted a randomized, controlled clinical trial assessing the efficacy of azithromycin-artesunate combination therapy. The study was conducted involving 228 patients aged 8-65 (...) years. Patients were randomized to 1 of 2 cohorts at a ratio of 2:1, receiving either azithromycin-artesunate once daily for 3 days (30 mg/kg per day of azithromycin plus 4 mg/kg per day of artesunate) or an adult dose of 80 mg of artemether plus 960 mg of lumefantrine (4 tablets Coartem or the equivalent for children weighing <35 kg) twice daily for 3 days.The 42-day cure rate by Kaplan-Meier analysis was 94.6% (95% confidence interval [CI], 89.38%-97.44%) in the azithromycin-artesunate arm

2010 EvidenceUpdates PubMed

46. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. (Full text)

Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. Azithromycin is recommended as therapy for cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa infection, but there has not been sufficient evidence to support the benefit of azithromycin in other patients with CF.To determine if azithromycin treatment improves lung function and reduces pulmonary exacerbations in pediatric CF patients (...) . Randomization was stratified by age of 6 to 12 years vs 13 to 18 years and by CF center.The active group (n = 131) received 250 mg (weight 18-35.9 kg) or 500 mg (weight > or = 36 kg) of azithromycin 3 days per week (Monday, Wednesday, and Friday) for 168 days. The placebo group (n = 129) received identically packaged placebo tablets on the same schedule.The primary outcome was change in FEV(1). Exploratory outcomes included additional pulmonary function end points, pulmonary exacerbations, changes in weight

2010 JAMA PubMed

47. The effect of azithromycin and Chlamydophilia pneumonia infection on expansion of small abdominal aortic aneurysms--a prospective randomized double-blind trial (Full text)

The effect of azithromycin and Chlamydophilia pneumonia infection on expansion of small abdominal aortic aneurysms--a prospective randomized double-blind trial The aim of the study was to evaluate the effect of azithromycin on the expansion rate of small abdominal aortic aneurysms (AAAs), and to determine whether or not a correlation exists between serological markers for Chlamydophilia pneumonia (Cpn) infection and AAA expansion.Nine vascular centers were included and 259 patients were invited (...) to participate. Ten patients declined and 2 patients had chronic kidney failure, leaving a total of 247 patients. Inclusion criteria were: AAA 35-49 mm and age <80 years. Patients were randomized to receive either azithromycin (Azithromax, Pfizer Inc, New York, NY) 600 mg once daily for 3 days and then 600 mg once weekly for 15 weeks, or placebo in identical tablets. The ultrasound scans were performed in a standardized way within a month before inclusion and every 6 months for a minimum follow-up time of 18

2009 EvidenceUpdates PubMed

48. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. (Full text)

Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. Mass oral azithromycin distribution to affected communities is a cornerstone of the World Health Organization's trachoma elimination program. Antibiotics are provided to target the ocular strains of chlamydia that cause trachoma, but may also be efficacious against respiratory disease, diarrhea, and malaria--frequent causes of childhood mortality in trachoma-endemic (...) areas.To compare mortality rates of participants aged 1 to 9 years in treated communities with those in untreated communities.We conducted a cluster-randomized clinical trial of mass azithromycin administration for trachoma control. Forty-eight communities (known as subkebeles) were randomized into 1 of 3 treatment schedules (annual treatment of all residents [15,902 participants], biannual treatment of all residents [17,288 participants], or quarterly treatment of children only [14,716 participants

2009 JAMA PubMed

49. Azithromycin-containing versus standard triple therapy for Helicobacter pylori eradication: a meta-analysis (Full text)

Azithromycin-containing versus standard triple therapy for Helicobacter pylori eradication: a meta-analysis Azithromycin-containing versus standard triple therapy for Helicobacter pylori eradication: a meta-analysis Azithromycin-containing versus standard triple therapy for Helicobacter pylori eradication: a meta-analysis Dong J, Yu XF, Zou J CRD summary The review concluded that azithromycin-containing triple therapy for first-line Helicobacter pylori eradication was equally effective (...) to standard triple eradication therapy and had a lower occurrence of side effects. In view of some potential limitations arising from the review process, and the overall average quality of included trials, the extent to which the authors’ conclusions are reliable is unclear. Authors' objectives To evaluate the safety and effectiveness of the addition of azithromycin to first-line Helicobacter pylori eradication regimes. Searching PubMed (from 1966), EMBASE (from 1980), Cochrane Central Register

2009 DARE. PubMed

50. Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis

Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

51. Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever). (Full text)

Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever). Enteric fever (typhoid and paratyphoid fever) is potentially fatal. Infection with drug-resistant strains of the causative organism Salmonella enterica serovar Typhi or Paratyphi increases morbidity and mortality. Azithromycin may have better outcomes in people with uncomplicated forms of the disease.To compare azithromycin with other antibiotics for treating uncomplicated enteric fever.In August 2008, we (...) searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2008, Issue 3), MEDLINE, EMBASE, LILACS, and mRCT. We also searched conference proceedings, reference lists, and contacted researchers and a pharmaceutical company.Randomized controlled trials comparing azithromycin with other antibiotics for treating children and adults with uncomplicated enteric fever confirmed by cultures of S. Typhi or Paratyphi in blood and/or stool.Both authors independently

2008 Cochrane PubMed

52. Is the frequency of recurrent chest infections, in children with chronic neurological problems, reduced by prophylactic azithromycin?

Is the frequency of recurrent chest infections, in children with chronic neurological problems, reduced by prophylactic azithromycin? BestBets: Is the frequency of recurrent chest infections, in children with chronic neurological problems, reduced by prophylactic azithromycin? Is the frequency of recurrent chest infections, in children with chronic neurological problems, reduced by prophylactic azithromycin? Report By: Charlotte B Kirk - Specialist Registrar in Paediatrics Search checked by Bob (...) Phillips - Section Editor, Archimedes Institution: Royal Hospital for Sick Children, Edinburgh, UK Date Submitted: 29th April 2008 Date Completed: 30th April 2008 Last Modified: 30th April 2008 Status: Green (complete) Three Part Question Do [children with chronic lung disease (not bronchopulmonary dysplasia) and/or bronchiectasis] who are [prescribed long-term azithromycin as prophylaxis] have a [reduction in frequency of respiratory exacerbations without a change in the bacterial flora found

2008 BestBETS

53. Azithromycin for acute lower respiratory tract infections. (Full text)

Azithromycin for acute lower respiratory tract infections. Acute lower respiratory tract infections (LRTI) range from acute bronchitis and acute exacerbations of chronic bronchitis to pneumonia. Approximately five million people die of acute respiratory tract infections annually. Among these, pneumonia represents the most frequent cause of mortality, hospitalization and medical consultation. Azithromycin is a new macrolide antibiotic, structurally modified from erythromycin and noted for its (...) activity against some gram-negative organisms associated with respiratory tract infections, particularly Haemophilus influenzae (H. influenzae).To compare the effectiveness of azithromycin to amoxycillin or amoxycillin/clavulanic acid (amoxyclav) in the treatment of LRTI, in terms of clinical failure, incidence of adverse events and microbial eradication.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007 Issue 2), MEDLINE (January 1966 to July 2007

2008 Cochrane PubMed

54. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. (PubMed)

Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Resistance to antibiotics is a major public-health problem, and studies that link antibiotic use and resistance have shown an association but not a causal effect. We used the macrolides azithromycin and clarithromycin to investigate the direct effect of antibiotic exposure on resistance in the oral streptococcal (...) flora of healthy volunteers.Volunteers were treated with azithromycin (n=74), clarithromycin (74), or placebo (76) in a randomised, double-blind trial. Pharyngeal swabs were obtained before and after administration of study treatment through 180 days. The proportion of streptococci that were macrolide resistant was assessed and the molecular basis of any change in resistance investigated. Analyses were done on an intent-to-treat basis. This study is registered with ClinicalTrials.gov, number

2007 Lancet

55. Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis

Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

56. Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials

Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

57. Single-dose azithromycin for the treatment of cholera in adults. (PubMed)

Single-dose azithromycin for the treatment of cholera in adults. Single-dose azithromycin is effective in the treatment of severe cholera in children, but its effectiveness in adults has not been evaluated.We conducted a double-blind, randomized trial comparing the equivalence of azithromycin and ciprofloxacin (each given in a single 1-g dose of two 500-mg tablets) among 195 men with severe cholera caused by Vibrio cholerae O1 or O139. Patients were hospitalized for five days. A stool culture (...) was performed daily. Primary outcome measures were clinical success (the cessation of watery stools within 48 hours after drug administration) and bacteriologic success (the inability to isolate V. cholerae after 48 hours).Therapy was clinically successful in 71 of 97 patients receiving azithromycin (73 percent) and in 26 of 98 patients receiving ciprofloxacin (27 percent) (P<0.001) and bacteriologically successful in 76 of 97 patients receiving azithromycin (78 percent) and in 10 of 98 patients receiving

2006 NEJM

58. A single dose of azithromycin was more effective than ciprofloxacin for severe cholera in men in Bangladesh

A single dose of azithromycin was more effective than ciprofloxacin for severe cholera in men in Bangladesh A single dose of azithromycin was more effective than ciprofloxacin for severe cholera in men in Bangladesh | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A single dose of azithromycin was more effective than ciprofloxacin for severe cholera in men in Bangladesh Article Text Therapeutics A single dose of azithromycin was more

2006 Evidence-Based Medicine (Requires free registration)

59. Azithromycin for the secondary prevention of coronary events. (PubMed)

Azithromycin for the secondary prevention of coronary events. Epidemiologic, laboratory, animal, and clinical studies suggest that there is an association between Chlamydia pneumoniae infection and atherogenesis. We evaluated the efficacy of one year of azithromycin treatment for the secondary prevention of coronary events.In this randomized, prospective trial, we assigned 4012 patients with documented stable coronary artery disease to receive either 600 mg of azithromycin or placebo weekly (...) for one year. The participants were followed for a mean of 3.9 years at 28 clinical centers throughout the United States.The primary end point, a composite of death due to coronary heart disease, nonfatal myocardial infarction, coronary revascularization, or hospitalization for unstable angina, occurred in 446 of the participants who had been randomly assigned to receive azithromycin and 449 of those who had been randomly assigned to receive placebo. There was no significant risk reduction

2005 NEJM

60. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. (Full text)

Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. Pilot studies suggest that a single, 2-g oral dose of azithromycin may be an alternative to a 2.4-MU intramuscular dose of penicillin G benzathine in the prevention and treatment of syphilis. We evaluated the efficacy of treatment with azithromycin in a developing country.A total of 328 subjects, 25 with primary and 303 with high-titer (a titer of at least 1:8 on a rapid plasmin reagin [RPR] test (...) ) latent syphilis, were recruited through screening of high-risk populations in Mbeya, Tanzania, and randomly assigned to receive 2 g of azithromycin orally (163 subjects) or 2.4 million units of penicillin G benzathine intramuscularly (165 subjects). The primary outcome was treatment efficacy, with cure defined serologically (a decline in the RPR titer of at least two dilutions by nine months after treatment) and, in primary syphilis, by epithelialization of ulcers within one or two weeks.The average

2005 NEJM PubMed